{"schema_version":"secwatch.filing_event.v1","accession":"0002007919-26-000044","form_type":"8-K","ticker":"INBX","cik":"0002007919","company_name":"Inhibrx Biosciences, Inc.","filed_at":"2026-08-13T20:10:15+00:00","discovered_at":"2026-08-13T20:12:10.238677+00:00","generated_at":"2026-08-13T20:12:44.893466+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Inhibrx Q2 net loss $36.7M; cash $219.5M post $100M Oxford loan; ozekibart PDUFA Apr 2027","bullets":["Net loss $36.7M ($2.34/share) vs $28.7M ($1.85/share) in Q2 2025; no revenue vs $1.3M prior year.","Cash $133.3M at June 30; $219.5M as of Aug 6 after $100M funded from $325M Oxford loan amendment.","FDA accepted BLA for ozekibart in chondrosarcoma; PDUFA date April 14, 2027.","INBRX-106 PFS data from Phase 2 HNSCC trial expected Q3 2026; new CRC cohorts initiated.","R&D $23.9M, G&A $8.3M, up from $22.3M and $6.4M respectively."],"urls":{"canonical":"https://secwatch.observer/filing/0002007919-26-000044","json":"https://secwatch.observer/filing/0002007919-26-000044.json","markdown":"https://secwatch.observer/filing/0002007919-26-000044.md","text":"https://secwatch.observer/filing/0002007919-26-000044.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2007919/000200791926000044/0002007919-26-000044-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2007919/000200791926000044/inhibrx-20260813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T20:12:44.893466+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}